CT011 / CARsgen - LARVOL DELTA

CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: CARsgen Therapeutics Co., Ltd.

CAR T-Cell Therapy • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection (GlobeNewswire) - "CARsgen Therapeutics Holdings Limited...announces that CT011, an autologous CAR T-cell product candidate against Glypican-3 (GPC3), has achieved Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for patients with GPC3-positive stage IIIa hepatocellular carcinoma who are at high risk of recurrence after surgical resection."

New trial • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen’s GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology (PRNewswire) - "CARsgen Therapeutics Holdings Limited...announces that a case report...has been published in Frontiers in Immunology....The published case reported a patient with advanced HCC who achieved a complete response (CR) and a long survival period after the combination therapy of CAR-GPC3 T-cell plus sorafenib....The CT011 plus sorafenib combination therapy was well tolerated. This patient obtained partial responses (PR) from the 3rd month and achieved CR in the 12th month after the first cycle of CT011 infusion. The tumor had no progression for more than 36 months and maintained the CR status for more than 24 months after the first infusion."

Clinical